Nectin 4 overexpression in ovarian cancer tissues and serum: Potential role as a serum biomarker

American Journal of Clinical Pathology

Volumn 134, Issue 5, 2010, Pages 835-845

  DeRycke, Melissa S ^a   Pambuccian, Stefan E ^a   Gilks, C Blake ^b   Kalloger, Steve E ^b   Ghidouche, Abderrezak ^c   Lopez, Marc ^c   Bliss, Robin L ^d   Geller, Melissa A ^d   Argenta, Peter A ^d   Harrington, Katherine M ^a   Skubitz, Amy P N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c INSTITUT PAOLI CALMETTES   (France)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Detection; Diagnosis; Nectin 4; Ovarian cancer; Serum biomarker; Tissue microarray

Indexed keywords

CA 125 ANTIGEN; NECTIN 4; TUMOR MARKER; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; LNIR PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GYNECOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING; METABOLISM; OVARY; OVARY TUMOR; RECEIVER OPERATING CHARACTERISTIC; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; OVARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78049514134     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPGXK0FR4MHIHB     Document Type: Article

References (33)

1. Boyle P, Levin B. World Cancer Report 2008. Lyon, France: International Agency for Research on Cancer; 2008.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
4. Verheijen RHM, von Mensdorff-Pouilly S, van Kamp GJ, et al. CA 125: fundamental and clinical aspects. Semin Cancer Biol. 1999;9:117-124.
5. Bast RC Jr, Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002;107:61-97.
6. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol. 2004;165:397-414. (Pubitemid 38971371)
7. Sakisaka T, Takai Y. Biology and pathology of nectins and nectin-like molecules. Curr Opin Cell Biol. 2004;16:513-521.
8. Sakisaka T, Ikeda W, Ogita H, et al. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol. 2007;19:593-602.
9. Yasumi M, Shimizu K, Honda T, et al. Role of each immunoglobulin-like loop of nectin for its cell-cell adhesion activity. Biochem Biophys Res Commun. 2003;302:61-66.
10. Yamada A, Fujita N, Sato T, et al. Requirement of nectin, but not cadherin, for formation of claudin-based tight junctions in annexin II-knockdown MDCK cells. Oncogene. 2006;25:5085-5102. (Pubitemid 44285978)
11. Irie K, Shimizu K, Sakisaka T, et al. Roles and modes of action of nectins in cell-cell adhesion. Semin Cell Dev Biol. 2004;15:643-656. (Pubitemid 39550244)
12. Fabre S, Reymond N, Cocchi F, et al. Prominent role of the Ig-like V domain in trans-interactions of nectins: nectin3 and nectin4 bind to the predicted C-C′-C″-D beta-strands of the nectin1 V domain. J Biol Chem. 2002;277:27006-27013.
13. Reymond N, Fabre S, Lecocq E, et al. Nectin4/PRR4, a new afadin-associated member of the nectin family that transinteracts with nectin1/PRR1 through V domain interaction. J Biol Chem. 2001;276:43205-43215. (Pubitemid 33691590)
14. Nakanishi H, Takai Y. Roles of nectins in cell adhesion, migration and polarization. Biol Chem. 2004;385:885-892. (Pubitemid 39481135)
15. Reymond N, Borg J-P, Lecocq E, et al. Human nectin3/PRR3: a novel member of the PVR/PRR/nectin family that interacts with afadin. Gene. 2000;255:347-355.
16. Fabre-Lafay S, Garrido-Urbani S, Reymond N, et al. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-α-converting enzyme (TACE)/ADAM-17. J Biol Chem. 2005;280:19543-19550. (Pubitemid 41379475)
17. Takano A, Ishikawa N, Nishino R, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69:6694-6703.
18. Fabre-Lafay S, Monville F, Garrido-Urbani S, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer. 2007;7:73-89. doi:10.1186/1471-2407-7-73.
19. Shaw TJ, Senterman MK, Dawson K, et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004;10:1032-1042.
20. Burleson KM, Hansen LK, Skubitz APN. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis. 2004;21:685-697.
21. Skubitz APN, Campbell KD, Goueli S, et al. Association of β1 integrin with protein kinase activity in large detergent resistant complexes. FEBS Lett. 1998;426:386-391. (Pubitemid 28218385)
22. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, et al. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 2006;66:4319-4328.
23. Nicosia SV, Wilbanks GD, Saunders B, et al. Cytology of human ovarian surface epithelial brushings. Cancer. 2004;102:1-10. (Pubitemid 38209567)
24. Kruk PK, Maines-Bandiera S, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest. 1990;63:132-136. (Pubitemid 20234682)
25. Fronhoffs S, Totzke G, Stier S, et al. A method for the rapid construction of cRNA standard curves in quantitative realtime reverse transcription polymerase chain reaction. Mol Cell Probes. 2002;16:99-110. (Pubitemid 34712934)
26. DeRycke MS, Andersen JD, Harrington KM, et al. S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival. Am J Clin Pathol. 2009;132:846-856.
27. Andersen JD, Boylan KLM, Xue FS, et al. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis. 2010;31:599-610.
28. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27:161-174.
29. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-163.
30. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239-1251.
31. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 Test, from biomarker discovery to FDA clearance. Clin Chem. 2010;56:327-329.
32. Herrmann R, Fayad W, Schwarz S, et al. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen. 2008;13:1-8.
33. Shield K, Ackland ML, Ahmed N, et al. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113:143-148.